Find Omega-3-Acid Ethyl Esters 90 manufacturers, exporters & distributors on PharmaCompass

Omega-3-Acid Ethyl Esters 90

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

36 API Suppliers, 18 USDMF, 23 CEP/COS, 4 JDMF, 22 KDMF, 3 Listed Suppliers

36 API Suppliers
18 USDMF
23 CEP/COS
4 JDMF
22 KDMF
3 Listed Suppliers

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

19 FDF Dossiers, 18 FDA Orange Book, 1 Listed Dossiers

19 FDF Dossiers
18 FDA Orange Book
1 Listed Dossiers

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 7 DKSH, 1 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 2 Actylis, 2 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 BASF, 10 Corel Pharma Chem, 1 Finar, 4 Gangwal Chemicals, 4 Ideal Cures Pvt Ltd, 13 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 1 Microlex e.U, 1 Novo Excipients, 1 Pluviaendo, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 2 Roquette, 7 Seppic, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

44 Coating Systems & Additives, 18 Controlled & Modified Release, 10 Film Formers & Plasticizers, 9 Empty Capsules, 8 Fillers, Diluents & Binders, 7 Thickeners and Stabilizers, 5 Emulsifying Agents, 5 Parenteral, 4 Direct Compression, 4 Topical, 4 Vegetarian Capsules, 4 API Stability Enhancers, 4 Coloring Agents, 4 Solubilizers, 2 Lubricants & Glidants, 2 Granulation, 2 Taste Masking, 1 Rheology Modifiers, 1 Chewable & Orodispersible Aids, 1 Co-Processed Excipients, 1 Disintegrants & Superdisintegrants

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 12 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
12 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 US Medicaid Prescriptions, 2 Finished Drug Prices, 11 Annual Reports

globalSalesInformation
2 US Medicaid Prescriptions
2 Finished Drug Prices
11 Annual Reports

MARKET PLACE

1 APIs, 1 FDF Dossiers

marketPlace
1 APIs
1 FDF Dossiers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

1DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

87,017,603

Annual Reports (USD Million)

2,203

Finished Drug Prices

81 RELATED EXCIPIENT COMPANIES

140EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 861006-80-6, Omacor, Coromega, Lotriga, Zodin, Ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate compound with ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate (1:1)

Molecular Formula

C₄₆H₇₀O₄

Molecular Weight

687.0 g/mol

InChI Key

DTMGIJFHGGCSLO-FIAQIACWSA-N

Omega-3-Acid Ethyl Esters is an ethyl ester form of omega-3 fatty acid derived from fish oil, with activity in decreasing serum triglyceride levels. Although its mechanism of action isn't known, omega-3-acid ethyl esters may work by decreasing the amount of triglycerides and other fats made in the liver.

1 2D Structure

Omega-3-Acid Ethyl Esters 90

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

2.1.2 InChI

InChI=1S/C24H36O2.C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26-4-2;1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18,20-21H,3-4,7,10,13,16,19,22-23H2,1-2H3;5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-,21-20-;6-5-,9-8-,12-11-,15-14-,18-17-

2.1.3 InChI Key

DTMGIJFHGGCSLO-FIAQIACWSA-N

2.1.4 Canonical SMILES

CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC

2.1.5 Isomeric SMILES

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Omacor

2. Omega-3 Ethyl Ester 90

3. P-om3 Adjunct

2.2.2 Depositor-Supplied Synonyms

1. 861006-80-6

2. Omacor

3. Coromega

4. Lotriga

5. Zodin

6. Ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate Compound With Ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate (1:1)

7. Omega-3 Acid Ethyl Esters

8. Omega-3-acid Ethyl Ester

9. Omega-3-acid Ethyl Esters

10. Chembl1200711

11. Tak-085

12. Omega-3-acid Ethyl Esters Type A

13. Icosapent (epa Ethyl Ester)

14. Doconexent (dha Ethyl Ester)

15. K-85

16. 4,7,10,13,16,19-docosahexaenoic Acid, Ethyl Ester, (4z,7z,10z,13z,16z,19z)-, Mixt. With (5z,8z,11z,14z,17z)-ethyl 5,8,11,14,17-eicosapentaenoate

17. Ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate

2.3 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₄₆H₇₀O₄
Molecular Weight	687.0 g/mol
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	31
Exact Mass	686.52741071 g/mol
Monoisotopic Mass	686.52741071 g/mol
Topological Polar Surface Area	52.6 Å²
Heavy Atom Count	50
Formal Charge	0
Complexity	916
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	11
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 4
Drug Name	Lovaza
Drug Label	LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a...
Active Ingredient	Omega-3-acid ethyl esters
Dosage Form	Capsule
Route	Oral
Strength	1gm contains at least 900mg of the ethyl esters of omega-3 fatty acids
Market Status	Prescription
Company	Smithkline Beecham

2 of 4
Drug Name	Omega-3-acid ethyl esters
Drug Label	LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a...
Active Ingredient	Omega-3-acid ethyl esters
Dosage Form	Capsule
Route	Oral
Strength	1gm contains at least 900mg of the ethyl esters of omega-3 fatty acids
Market Status	Prescription
Company	Apotex; Teva Pharms Usa; Par Pharm

3 of 4
Drug Name	Lovaza
Drug Label	LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a...
Active Ingredient	Omega-3-acid ethyl esters
Dosage Form	Capsule
Route	Oral
Strength	1gm contains at least 900mg of the ethyl esters of omega-3 fatty acids
Market Status	Prescription
Company	Smithkline Beecham

4 of 4
Drug Name	Omega-3-acid ethyl esters
Drug Label	LOVAZA, a lipid-regulating agent, is supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of LOVAZA contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a...
Active Ingredient	Omega-3-acid ethyl esters
Dosage Form	Capsule
Route	Oral
Strength	1gm contains at least 900mg of the ethyl esters of omega-3 fatty acids
Market Status	Prescription
Company	Apotex; Teva Pharms Usa; Par Pharm

4.2 Drug Indication

Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (500 mg/dL) hypertriglyceridemia (HTG).

FDA Label

5 Pharmacology and Biochemistry

5.1 Pharmacology

Omega-3-acid ethyl esters reduce triglyceride production, increase fatty acid metabolism, inhibit the release of fatty acids, increase triglyceride clearance, and decrease production of very low density lipoprotein cholesterol(VLDL-C).

5.2 FDA Pharmacological Classification

5.2.1 Pharmacological Classes

Omega-3 Fatty Acid [EPC]; Fatty Acids, Omega-3 [CS]

5.3 Absorption, Distribution and Excretion

Absorption

Omega-3-acid ethyl esters are rapidly hydrolysed to free fatty acids in the intestinal lumen which then become incorporated into phospholipids, cholesterol, and triglycerides so determination of bioavailability by serum concentration is not possible.

Route of Elimination

Includes oxidative catabolism to carbon dioxide and water

Volume of Distribution

82 56L

Clearance

757 mL/h 283mL/h.

5.4 Metabolism/Metabolites

Omega-3-acid ethyl esters are hydrolysed to free fatty acids in the intestinal lumen by pancreatic lipase. Once in enterocytes, the free fatty acids are packaged in chylomicrons which are released from cells into the circulation. Fatty acids then enter the liver where they can be incorporated into liver stores, incorporated into lipoprotein phospholipids, or oxidised for energy.

5.5 Biological Half-Life

79 hours 47 hours.

5.6 Mechanism of Action

Omega-3-acid ethyl esters reduce triglyceride production by the liver but this mechanism is not well understood. Omega-3-acid ethyl esters inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, reducing triglyceride synthesis and increasing paroxysmal beta-oxidation, which increases fatty aside metabolism. Omega-3-acid ethyl esters also inhibit the release of fatty acids by competing for enzymes involved in the synthesis of triglycerides, increase triglyceride clearance by increasing the activity of lipoprotein lipase, and decrease production of VLDL-C.

API SUPPLIERS